European Equities Traded in the US as ADRs Are Little Changed in Friday Trading

MT Newswires Live
Sep 05

European equities traded in the US as American depositary receipts were little changed late Friday morning with the S&P Europe Select ADR Index rising less than 0.1% to 1,520.44.

From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and semiconductor company Sequans Communications (SQNS), which advanced 10% and 7% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and biotech company Evaxion (EVAX), which climbed 5.7% and 4.5% respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and pharmaceutical company Novo Nordisk (NVO), which dropped 4.5% and 2.1% respectively. They were followed by oil and gas company Eni (E) and petroleum refiner Equinor (EQNR), which lost 1.9% and 1.5% respectively.

From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and software firm Endava (DAVA), which rose 3.1% and 2.2% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and utilities company National Grid (NGG), which were up 1.6% and 1.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and financial services company Barclays (BCS), which fell 5.7% and 2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and oil and gas company BP (BP), which were down 1.7% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10